High mitochondria content is associated with prostate cancer disease progressionReportar como inadecuado

High mitochondria content is associated with prostate cancer disease progression - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Molecular Cancer

, 12:145

First Online: 21 November 2013Received: 27 August 2013Accepted: 15 November 2013DOI: 10.1186-1476-4598-12-145

Cite this article as: Grupp, K., Jedrzejewska, K., Tsourlakis, M.C. et al. Mol Cancer 2013 12: 145. doi:10.1186-1476-4598-12-145


BackgroundMitochondria are suggested to be important organelles for cancer initiation and promotion. This study was designed to evaluate the prognostic value of MTC02, a marker for mitochondrial content, in prostate cancer.

MethodsImmunohistochemistry of using an antibody against MTC02 was performed on a tissue microarray TMA containing 11,152 prostate cancer specimens. Results were compared to histological phenotype, biochemical recurrence, ERG status and other genomic deletions by using our TMA attached molecular information.

ResultsTumor cells showed stronger MTC02 expression than normal prostate epithelium. MTC02 immunostaining was found in 96.5% of 8,412 analyzable prostate cancers, including 15.4% tumors with weak, 34.6% with moderate, and 46.5% with strong expression. MTC02 expression was associated with advanced pathological tumor stage, high Gleason score, nodal metastases p < 0.0001 each, positive surgical margins p = 0.0005, and early PSA recurrence p < 0.0001 if all cancers were jointly analyzed. Tumors harboring ERG fusion showed higher expression levels than those without p < 0.0001. In ERG negative prostate cancers, strong MTC02 immunostaining was linked to deletions of PTEN, 6q15, 5q21, and early biochemical recurrence p < 0.0001 each. Moreover, multiple scenarios of multivariate analyses suggested an independent association of MTC02 with prognosis in preoperative settings.

ConclusionsOur study demonstrates high-level MTC02 expression in ERG negative prostate cancers harboring deletions of PTEN, 6q15, and 5q21. Additionally, increased MTC02 expression is a strong predictor of poor clinical outcome in ERG negative cancers, highlighting a potentially important role of elevated mitochondrial content for prostate cancer cell biology.

KeywordsMTC02 ERG Prostate cancer Tissue microarray Electronic supplementary materialThe online version of this article doi:10.1186-1476-4598-12-145 contains supplementary material, which is available to authorized users.

Katharina Grupp, Karolina Jedrzejewska contributed equally to this work.

Download fulltext PDF

Autor: Katharina Grupp - Karolina Jedrzejewska - Maria Christina Tsourlakis - Christina Koop - Waldemar Wilczak - Meike Adam - Ale

Fuente: https://link.springer.com/

Documentos relacionados